Lilly suspends small studies of pipeline drug prasugrel
Eli Lilly said it is suspending two small studies of its most promising pipeline candidate, the blood-thinner prasugrel, after data raised concerns about the dosage used in certain patient groups.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.